KR20150097660A - Cftr 채널을 억제하기 위한 트리시클릭 화합물 - Google Patents

Cftr 채널을 억제하기 위한 트리시클릭 화합물 Download PDF

Info

Publication number
KR20150097660A
KR20150097660A KR1020157019061A KR20157019061A KR20150097660A KR 20150097660 A KR20150097660 A KR 20150097660A KR 1020157019061 A KR1020157019061 A KR 1020157019061A KR 20157019061 A KR20157019061 A KR 20157019061A KR 20150097660 A KR20150097660 A KR 20150097660A
Authority
KR
South Korea
Prior art keywords
dione
pyrimido
pyrrolo
dimethyl
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020157019061A
Other languages
English (en)
Korean (ko)
Inventor
마붑 아메드
알렉산더 애셜-켈리
루이저 귀리츠
제프리 매케너
조지프 매케너
사이먼 머튼
라케시 파머
존 셰퍼드
폴 라이트
Original Assignee
노파르티스 아게
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50030372&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR20150097660(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 노파르티스 아게 filed Critical 노파르티스 아게
Publication of KR20150097660A publication Critical patent/KR20150097660A/ko
Withdrawn legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D513/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/12Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
    • C07D513/14Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12Antidiarrhoeals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/22Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains four or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/14Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D513/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
KR1020157019061A 2012-12-19 2013-12-17 Cftr 채널을 억제하기 위한 트리시클릭 화합물 Withdrawn KR20150097660A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261739335P 2012-12-19 2012-12-19
US61/739,335 2012-12-19
US201361906141P 2013-11-19 2013-11-19
US61/906,141 2013-11-19
PCT/IB2013/061043 WO2014097148A1 (en) 2012-12-19 2013-12-17 Tricyclic compounds for inhibiting the cftr channel

Publications (1)

Publication Number Publication Date
KR20150097660A true KR20150097660A (ko) 2015-08-26

Family

ID=50030372

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020157019061A Withdrawn KR20150097660A (ko) 2012-12-19 2013-12-17 Cftr 채널을 억제하기 위한 트리시클릭 화합물

Country Status (25)

Country Link
US (2) US20140171417A1 (enExample)
EP (1) EP2935278B1 (enExample)
JP (1) JP6284546B2 (enExample)
KR (1) KR20150097660A (enExample)
CN (1) CN105143230B (enExample)
AP (1) AP2015008539A0 (enExample)
AR (1) AR094122A1 (enExample)
AU (1) AU2013365739A1 (enExample)
BR (1) BR112015014292A2 (enExample)
CA (1) CA2895660A1 (enExample)
CL (1) CL2015001730A1 (enExample)
CR (1) CR20150325A (enExample)
CU (1) CU20150066A7 (enExample)
EA (1) EA201591177A1 (enExample)
ES (1) ES2628369T3 (enExample)
HK (1) HK1209741A1 (enExample)
IL (1) IL239389A0 (enExample)
MX (1) MX2015007939A (enExample)
PE (1) PE20151055A1 (enExample)
PH (1) PH12015501386A1 (enExample)
SG (1) SG11201504594QA (enExample)
TN (1) TN2015000279A1 (enExample)
TW (1) TW201429974A (enExample)
UY (1) UY35211A (enExample)
WO (1) WO2014097148A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2755652B1 (en) 2011-09-16 2021-06-02 Novartis AG N-substituted heterocyclyl carboxamides
CN105143230B (zh) 2012-12-19 2017-06-09 诺华股份有限公司 用于抑制cftr通道的三环化合物
EA201591175A1 (ru) * 2012-12-19 2015-11-30 Новартис Аг Трициклические соединения в качестве ингибиторов cftr
TWI686429B (zh) 2014-09-19 2020-03-01 美商摩曼帝夫特性材料公司 用於經控制之矽氧烷交聯的鉑(ii)二烯錯合物
HUE054399T2 (hu) * 2015-04-23 2021-09-28 Trevi Therapeutics Inc Vegyületek viszketéses állapotok kezelésére
CN106478558B (zh) * 2016-10-17 2019-03-29 天津雅奥科技发展有限公司 一种4-羟甲基-二氢-呋喃-2(3h)-酮的合成方法
EP3911649A1 (en) * 2019-01-17 2021-11-24 F. Hoffmann-La Roche AG A process for the preparation of tetrahydropyridopyrimidines
JP7669295B2 (ja) * 2019-06-12 2025-04-28 ザ・リージエンツ・オブ・ザ・ユニバーシテイー・オブ・カリフオルニア 胆汁酸性下痢を治療する方法
WO2022232634A1 (en) 2021-04-29 2022-11-03 Novartis Ag Deubiquitinase-targeting chimeras and related methods
CN117654560B (zh) * 2023-12-01 2024-06-04 安徽泽升科技股份有限公司 一种通过氧化氨基连续化制备硝基化合物的方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60025616T2 (de) 1999-08-25 2006-11-30 Banyu Pharmaceutical Co., Ltd. Isoindolderivate
JP2002255967A (ja) 2001-02-27 2002-09-11 Banyu Pharmaceut Co Ltd イソインドール誘導体を有効成分とする糖尿病の治療剤、糖尿病の慢性合併症の予防剤又は肥満の治療剤。
WO2004078163A2 (en) 2003-02-28 2004-09-16 Transform Pharmaceuticals, Inc. Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
KR20090087487A (ko) 2006-12-12 2009-08-17 쉐링 코포레이션 아스파르틸 프로테아제 억제제
US20110015137A1 (en) * 2007-07-05 2011-01-20 Trustees Of Boston University Reca inhibitors and their uses as microbial inhibitors or potentiators of antibiotic activity
US8642660B2 (en) 2007-12-21 2014-02-04 The University Of Rochester Method for altering the lifespan of eukaryotic organisms
WO2011019737A1 (en) * 2009-08-10 2011-02-17 The Regents Of The University Of California Pyrimido-pyrrolo-quinoxalinedione inhibitors of cystic fibrosis transmembrane conductance regulator protein and uses therefor
WO2012166658A1 (en) * 2011-05-27 2012-12-06 The Regents Of The University Of California Pyrimido-pyrrolo-oxazine-dione compound inhibitors of the cystic fibrosis transmembrane conductance regulator protein and uses therefor
CN105143230B (zh) 2012-12-19 2017-06-09 诺华股份有限公司 用于抑制cftr通道的三环化合物
EA201591175A1 (ru) * 2012-12-19 2015-11-30 Новартис Аг Трициклические соединения в качестве ингибиторов cftr

Also Published As

Publication number Publication date
WO2014097148A1 (en) 2014-06-26
CN105143230B (zh) 2017-06-09
UY35211A (es) 2014-07-31
PH12015501386A1 (en) 2015-09-02
CR20150325A (es) 2015-08-10
IL239389A0 (en) 2015-07-30
CN105143230A (zh) 2015-12-09
SG11201504594QA (en) 2015-07-30
HK1209741A1 (en) 2016-04-08
EP2935278B1 (en) 2017-03-15
EA201591177A1 (ru) 2015-11-30
CU20150066A7 (es) 2015-11-27
JP6284546B2 (ja) 2018-02-28
ES2628369T3 (es) 2017-08-02
BR112015014292A2 (pt) 2017-07-11
AP2015008539A0 (en) 2015-06-30
WO2014097148A9 (en) 2015-02-19
PE20151055A1 (es) 2015-08-05
AU2013365739A1 (en) 2015-07-09
MX2015007939A (es) 2016-03-11
TN2015000279A1 (en) 2016-10-03
US20150336986A1 (en) 2015-11-26
CL2015001730A1 (es) 2015-08-28
JP2016509579A (ja) 2016-03-31
TW201429974A (zh) 2014-08-01
US9359381B2 (en) 2016-06-07
CA2895660A1 (en) 2014-06-26
AR094122A1 (es) 2015-07-08
US20140171417A1 (en) 2014-06-19
EP2935278A1 (en) 2015-10-28

Similar Documents

Publication Publication Date Title
KR20150097660A (ko) Cftr 채널을 억제하기 위한 트리시클릭 화합물
JP6629847B2 (ja) 縮合五員環イミダゾール誘導体
TWI662030B (zh) 適用作pim激酶抑制劑之噻唑甲醯胺及吡啶甲醯胺化合物
CN115485278A (zh) 通过缀合btk抑制剂与e3连接酶配体降解布鲁顿氏酪氨酸激酶(btk)及其使用方法
JP6284545B2 (ja) Cftr阻害としての三環式化合物
WO2023001133A1 (zh) Prmt5抑制剂
CN105073715A (zh) 二氢哒嗪-3,5-二酮衍生物
US20250179093A1 (en) Kras modulators
TW202513063A (zh) 用於治療癌症及其他適應症之稠合吡啶
CN115873000A (zh) 异喹啉酮类及喹唑啉酮类化合物及其组合物和用途
TW202016116A (zh) 作為a2a受體拮抗劑的吡唑並三唑並嘧啶衍生物
WO2022166796A1 (zh) 嘧啶或吡啶并杂环类腺苷受体抑制剂及其制备方法和用途
HK1216424B (en) Thiazolecarboxamides and pyridinecarboxamide compounds useful as pim kinase inhibitors

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20150715

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PC1203 Withdrawal of no request for examination
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid